Exploring the association of ESR1 and ESR2 gene SNPs with polycystic ovary syndrome in human females: a comprehensive association study.
Coding sequence
Polycystic ovary syndrome
Secondary structure
Single nucleotide polymorphisms
Sub-cellular localization
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
29 Jan 2024
29 Jan 2024
Historique:
received:
10
09
2023
accepted:
25
12
2023
medline:
29
1
2024
pubmed:
29
1
2024
entrez:
28
1
2024
Statut:
epublish
Résumé
Polycystic Ovary Syndrome (PCOS) affects a significant proportion of human females worldwide and is characterized by hormonal, metabolic, and reproductive dysfunctions, including infertility, irregular menstrual cycles, acanthosis nigricans, and hirsutism. Mutations in the estrogen receptor genes ESR1 and ESR2, involved in normal follicular development and ovulation, can contribute to development of the PCOS. The present study focuses on investigating the potential correlation between single nucleotide polymorphisms (SNPs) of ESR1 and ESR2 genes and the incidence of this syndrome. For this study, SNPs in ESR1 and ESR2 genes were retrieved from the ENSEMBL database and analyzed for their effect on mutated proteins using different bioinformatics tools including SIFT, PolyPhen, CADD, REVEL, MetaLR, I-Mutant, CELLO2GO, ProtParam, SOPMA, SWISS-MODEL and HDDOCK. All the SNPs documented in the present study were deleterious. All the SNPs except rs1583384537, rs1450198518, and rs78255744 decreased protein stability. Two variants rs1463893698 and rs766843910 in the ESR2 gene altered the localization of mutated proteins i.e. in addition to the nucleus, proteins were also found in mitochondria and extracellular, respectively. SNPs rs104893956 in ESR1 and rs140630557, rs140630557, rs1596423459, rs766843910, rs1596405923, rs762454979 and rs1384121511 in ESR2 gene significantly changed the secondary structure of proteins (2D). SNPs that markedly changed 3D configuration included rs1554259481, rs188957694 and rs755667747 in ESR1 gene and rs1463893698, rs140630557, rs1596423459, rs766843910, rs1596405923, rs762454979 and rs1384121511 in ESR2 gene. Variants rs1467954450 (ESR1) and rs140630557 (ESR2) were identified to reduce the binding tendency of ESRα and β receptors with estradiol as reflected by the docking scores i.e. -164.97 and -173.23, respectively. Due to the significant impact on the encoded proteins, these variants might be proposed as biomarkers to predict the likelihood of developing PCOS in the future and for diagnostic purposes.
Sections du résumé
BACKGROUND
BACKGROUND
Polycystic Ovary Syndrome (PCOS) affects a significant proportion of human females worldwide and is characterized by hormonal, metabolic, and reproductive dysfunctions, including infertility, irregular menstrual cycles, acanthosis nigricans, and hirsutism. Mutations in the estrogen receptor genes ESR1 and ESR2, involved in normal follicular development and ovulation, can contribute to development of the PCOS. The present study focuses on investigating the potential correlation between single nucleotide polymorphisms (SNPs) of ESR1 and ESR2 genes and the incidence of this syndrome.
METHODS
METHODS
For this study, SNPs in ESR1 and ESR2 genes were retrieved from the ENSEMBL database and analyzed for their effect on mutated proteins using different bioinformatics tools including SIFT, PolyPhen, CADD, REVEL, MetaLR, I-Mutant, CELLO2GO, ProtParam, SOPMA, SWISS-MODEL and HDDOCK.
RESULTS
RESULTS
All the SNPs documented in the present study were deleterious. All the SNPs except rs1583384537, rs1450198518, and rs78255744 decreased protein stability. Two variants rs1463893698 and rs766843910 in the ESR2 gene altered the localization of mutated proteins i.e. in addition to the nucleus, proteins were also found in mitochondria and extracellular, respectively. SNPs rs104893956 in ESR1 and rs140630557, rs140630557, rs1596423459, rs766843910, rs1596405923, rs762454979 and rs1384121511 in ESR2 gene significantly changed the secondary structure of proteins (2D). SNPs that markedly changed 3D configuration included rs1554259481, rs188957694 and rs755667747 in ESR1 gene and rs1463893698, rs140630557, rs1596423459, rs766843910, rs1596405923, rs762454979 and rs1384121511 in ESR2 gene. Variants rs1467954450 (ESR1) and rs140630557 (ESR2) were identified to reduce the binding tendency of ESRα and β receptors with estradiol as reflected by the docking scores i.e. -164.97 and -173.23, respectively.
CONCLUSION
CONCLUSIONS
Due to the significant impact on the encoded proteins, these variants might be proposed as biomarkers to predict the likelihood of developing PCOS in the future and for diagnostic purposes.
Identifiants
pubmed: 38281964
doi: 10.1186/s13048-023-01335-7
pii: 10.1186/s13048-023-01335-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Informations de copyright
© 2024. The Author(s).
Références
Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–97.
pubmed: 17720020
doi: 10.1016/S0140-6736(07)61345-2
Walters KA, Gilchrist RB, Ledger WL, Teede HJ, Handelsman DJ, Campbell RE. New perspectives on the pathogenesis of PCOS: neuroendocrine origins. Trends Endocrinol Metab. 2018;29:841–52.
pubmed: 30195991
doi: 10.1016/j.tem.2018.08.005
Muccee F, Bijou O, Harakeh S, Adawiyah R, Sayyed RZ, Haghshenas L, Alshehri D, Ansari MJ, Ghazanfar S. In-Silico investigation of effects of single-nucleotide polymorphisms in PCOS-associated CYP11A1 gene on mutated proteins. Genes. 2022;13:1231.
pubmed: 35886014
pmcid: 9317558
doi: 10.3390/genes13071231
Tay CT, Hart RJ, Hickey M, Moran LJ, Earnest A, Doherty DA, Teede HJ, Joham AE. Updated adolescent diagnostic criteria for polycystic ovary syndrome: impact on prevalence and longitudinal body mass index trajectories from birth to adulthood. BMC Med. 2020;18:1–11.
doi: 10.1186/s12916-020-01861-x
Jacewicz-Święcka M, Kowalska I. Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies. Diabetes Metab Res Rev. 2018;34: e3054.
pubmed: 30089337
doi: 10.1002/dmrr.3054
Allahbadia GN, Merchant R. Polycystic ovary syndrome in the Indian Subcontinent. Semin Reprod Med. 2008;26:022–34.
doi: 10.1055/s-2007-992921
Zhang T, Liang W, Fang M, Yu J, Ni Y, Li Z. Association of the CAG repeat polymorphisms in androgen receptor gene with polycystic ovary syndrome: a systemic review and meta-analysis. Gene. 2013;524:161–7.
pubmed: 23628801
doi: 10.1016/j.gene.2013.04.040
Pusalkar M, Meherji P, Gokral J, Chinnaraj S, Maitra A. CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome. Fertil Steril. 2009;92:653–9.
pubmed: 18725155
doi: 10.1016/j.fertnstert.2008.07.016
Peng CY, Xie HJ, Guo ZF, Nie YL, Chen J, Zhou JM, Yin J. The association between androgen receptor gene CAG polymorphism and polycystic ovary syndrome: a case-control study and meta-analysis. J Assist Reproduct Genet. 2014;31:1211–9.
doi: 10.1007/s10815-014-0286-0
Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): current perspectives. Appl Clin Genet. 2019;12:249.
pubmed: 31920361
pmcid: 6935309
doi: 10.2147/TACG.S200341
Zhang B, Zhou W, Shi Y, Zhang J, Cui L, Chen ZJ. Lifestyle and environmental contributions to ovulatory dysfunction in women of polycystic ovary syndrome. BMC Endocr Disord. 2020;20:1–7.
doi: 10.1186/s12902-020-0497-6
Ashraf S, Nabi M, Rashid F, Amin S. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egypt J Med Hum Genet. 2019;20:1–10.
doi: 10.1186/s43042-019-0031-4
De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003;24:633–67.
pubmed: 14570747
doi: 10.1210/er.2002-0015
Gennari L, Merlotti D, De Paola V, Calabro A, Becherini L, Martini G, Nuti R. Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review. Am J Epidemiol. 2005;161:307–20.
pubmed: 15692074
doi: 10.1093/aje/kwi055
Tang ZR, Zhang R, Lian ZX, Deng SL, Yu K. Estrogen-receptor expression and function in female reproductive disease. Cells. 2019;8:1123.
pubmed: 31546660
pmcid: 6830311
doi: 10.3390/cells8101123
Chauvin S, Cohen-Tannoudji J, Guigon CJ. Estradiol signaling at the heart of folliculogenesis: its potential deregulation in human ovarian pathologies. Int J Mol Sci. 2022;23:512.
pubmed: 35008938
pmcid: 8745567
doi: 10.3390/ijms23010512
Xu XL, Deng SL, Lian ZX, Yu K. Estrogen receptors in polycystic ovary syndrome. Cells. 2021;10:459.
pubmed: 33669960
pmcid: 7924872
doi: 10.3390/cells10020459
Walters KA. Polycystic ovary syndrome: Is it androgen or estrogen receptor? Curr Opin Endocr Metab Res. 2020;12:1–7.
doi: 10.1016/j.coemr.2020.01.003
Segawa T, Teramoto S, Omi K, Miyauchi O, Watanabe Y, Osada H. Changes in estrone and estradiol levels during follicle development: a retrospective large-scale study. Reprod Biol Endocr. 2015;13:1–7.
doi: 10.1186/s12958-015-0051-y
Arao Y, Korach KS. The F domain of estrogen receptor α is involved in species-specific, tamoxifen-mediated transactivation. J Biol Chem. 2018;293:8495–507.
pubmed: 29632071
pmcid: 5986198
doi: 10.1074/jbc.RA117.001212
Liu F, Tian L, Tan J, Li Z, Qin H, Xu D, Huang Z, Wu X, Chen G, Wu Q. Identification of a novel ESR1 mutation in a Chinese PCOS woman with estrogen insensitivity in IVF treatment. Reprod Biol Endocrinol. 2022;20:157.
pubmed: 36401248
pmcid: 9673392
doi: 10.1186/s12958-022-01029-7
Villavicencio A, Bacallao K, Avellaira C, Gabler F, Fuentes A, Vega M. Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. Gynecol Oncol. 2006;103:307–14.
pubmed: 16677694
doi: 10.1016/j.ygyno.2006.03.029
Maliqueo M, Clementi M, Gabler F, Johnson MC, Palomino A, Sir-Petermann T, Vega M. Expression of steroid receptors and proteins related to apoptosis in endometria of women with polycystic ovary syndrome. Fertil Steril. 2003;80:812–9.
pubmed: 14505758
doi: 10.1016/S0015-0282(03)00987-7
Liaqat I, Jahan N, Krikun G, Taylor HS. Genetic polymorphisms in Pakistani women with polycystic ovary syndrome. Reprod Sci. 2015;22:347–57.
pubmed: 25100445
doi: 10.1177/1933719114542015
Jiao X, Chen W, Zhang J, Wang W, Song J, Chen D, Zhu W, Shi Y, Yu X. Variant alleles of the ESR1, PPARG, HMGA2, and MTHFR genes are associated with polycystic ovary syndrome risk in a Chinese population: a case-control study. Front Endocrinol. 2018;9:504.
doi: 10.3389/fendo.2018.00504
Zhou S, Wen S, Sheng Y, Yang M, Shen X, Chen Y, Kang D, Xu L. Association of estrogen receptor genes polymorphisms with polycystic ovary syndrome: a systematic review and meta-analysis based on observational studies. Front Endocrinol. 2021;12: 726184.
doi: 10.3389/fendo.2021.726184
Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003;31:3784–8.
pubmed: 12824418
pmcid: 168970
doi: 10.1093/nar/gkg563
Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40:W452–7.
pubmed: 22689647
pmcid: 3394338
doi: 10.1093/nar/gks539
Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;76:21–7.
Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47:D886–94.
pubmed: 30371827
doi: 10.1093/nar/gky1016
Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, Liu X. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet. 2015;24:2125–37.
pubmed: 25552646
doi: 10.1093/hmg/ddu733
Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99:877–85.
pubmed: 27666373
pmcid: 5065685
doi: 10.1016/j.ajhg.2016.08.016
Kulshreshtha S, Chaudhary V, Goswami GK, Mathur N. Computational approaches for predicting mutant protein stability. J Comput Aided Mol Des. 2016;30:401–12.
pubmed: 27160393
doi: 10.1007/s10822-016-9914-3
Yu CS, Cheng CW, Su WC, Chang KC, Huang SW, Hwang JK, Lu CH. CELLO2GO: a web server for protein subCELlular LOcalization prediction with functional gene ontology annotation. PLoS One. 2014;9: e99368.
pubmed: 24911789
pmcid: 4049835
doi: 10.1371/journal.pone.0099368
Geourjon C, Deleage G. SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Bioinform. 1995;11:681–4.
doi: 10.1093/bioinformatics/11.6.681
Ishida T, Kinoshita K. PrDOS: prediction of disordered protein regions from amino acid sequence. Nucleic Acids Res. 2007;35:W460–4.
pubmed: 17567614
pmcid: 1933209
doi: 10.1093/nar/gkm363
Sheik SS, Sundararajan P, Hussain ASZ, Sekar K. Ramachandran plot on the web Bioinform. 2002;18:1548–9.
Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2:1511–9.
pubmed: 8401235
pmcid: 2142462
doi: 10.1002/pro.5560020916
Hollingsworth SA, Karplus PA. A fresh look at the Ramachandran plot and the occurrence of standard structures in proteins. Biomol Concepts. 2010;1:271–83.
pubmed: 21436958
pmcid: 3061398
doi: 10.1515/bmc.2010.022
Douma Z, Dallel M, Bahia W, Salem AB, Ali FHB, Almawi WY, Lautier C, Haydar S, Grigorescu F, Mahjoub T. Association of estrogen receptor gene variants (ESR1 and ESR2) with polycystic ovary syndrome in Tunisia. Gene. 2020;741: 144560.
pubmed: 32169631
doi: 10.1016/j.gene.2020.144560
Mir R, Tayeb FJ, Barnawi J, Jalal MM, Saeedi NH, Hamadi A, Altayar MA, Alshammari SE, Mtiraoui N, Ali ME. Biochemical characterization and molecular determination of estrogen Receptor-α (ESR1 PvuII-rs2234693 T> C) and MiRNA-146a (rs2910164 C> G) polymorphic gene variations and their association with the risk of polycystic ovary syndrome. Int J Environ Res Public Health. 2022;19:3114.
pubmed: 35270805
pmcid: 8910123
doi: 10.3390/ijerph19053114
Al-Jumaili EFA. Allelic estrogen receptor beta (ESR2) gene association with Polycystic Ovary Syndrome in unmarried Iraqi female of Baghdad governorate. Iraqi J Biotechnol. 2019;18:26–32.
Morya VK, Yadav S, Kim EK, Yadav D. In silico characterization of alkaline proteases from different species of Aspergillus. Appl Biochem Biotechnol. 2012;166:243–57.
pubmed: 22072140
doi: 10.1007/s12010-011-9420-y
Gamage DG, Gunaratne A, Periyannan GR, Russell TG. Applicability of instability index for in vitro protein stability prediction. Protein Pept Lett. 2019;26:339–47.
pubmed: 30816075
doi: 10.2174/0929866526666190228144219
Jin YT, Jin TY, Zhang ZL, Ye YN, Deng Z, Wang J, Guo FB. Quantitative elucidation of associations between nucleotide identity and physicochemical properties of amino acids and the functional insight. J Comput Struct Biotechnol. 2021;19:4042–8.
doi: 10.1016/j.csbj.2021.07.012
Campello RS, Fátima LA, Barreto-Andrade JN, Lucas TF, Mori RC, Porto CS, Machado UF. Estradiol-induced regulation of GLUT4 in 3T3-L1 cells: involvement of ESR1 and AKT activation. J Mol Endocrinol. 2017;59:257–68.
pubmed: 28729437
doi: 10.1530/JME-17-0041
Uzar I, Bogacz A, Sowińska-Przepiera E, Kotrych K, Wolek M, Sulikowski T, Kamiński A. The influence of ESR1 polymorphisms on selected hormonal, metabolic and mineral balance markers in women with hyperandrogenism. Sci Rep. 2022;12:19712.
pubmed: 36385124
pmcid: 9668905
doi: 10.1038/s41598-022-17383-w